Help-Medical.Net

Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional optimistic matter from its Discontinue 2 program seeking RDEA594, its steer outcome aspirant quest of the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted in general the European Coalition Against Rheumatism (EULAR) in Rome, Italy.  RDEA594, a first-in-class picky inhibitor of the URAT1 transporter, treats the Read the rest of this entry »

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its head-to-head Point of view III clinical whack of Cayston®(aztreonam in compensation inhalation figuring out versus tobramycin inhalation mixing (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved ditty of its co-primary endpoints of non-inferiority seeking medium percent alteration in false expiratory mass in people tick (FEV1) percent predicted Read the rest of this entry »

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the Presence when one pleases the hour figures object of its FDA-approved diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes analgesic aspirant BYDUREON™ (exenatide extended-release on injectable disbarment at the American Diabetes Association’s (ADA’s) 70th Annual Meticulous Sessions being held in Orlando, Read the rest of this entry »

Sensitive Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the production of additional results from BLISS-52, one of two radical Gradually eliminate 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The additional statistics last wishes as be presented in Rome at the 2010 Congress of the European Unite against Rheumatism (EULAR) on Saturday, June 19.

Read the rest of this entry »

Fire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that matter is being presented on denufosol tetrasodium, an investigational treatment as regards cystic fibrosis (CF), during an vocalized demonstration and flier presentations at the 33rd Annual European Cystic Fibrosis Academy (ECFS) Talk June 16 – 19, 2010 in Valencia, Spain. The matter from Inspire’s basic Appearance 3 clinical attempt with denufosol, TIGER-1, set forward that denufosol, Read the rest of this entry »

XOMA Ltd. (Nasdaq:XOMA), a kingpin in the finding and improvement of corrective antibodies, announced practical results from an open-label lead scan of XOMA 052 in patients with uveitis of Behcet’s illness who were affliction from vision-threatening exacerbations undeterred by maximal doses of immunosuppressive medicines. All seven patients who enrolled in the nuisance displayed swift reduction of intraocular swelling and enhancement in visual Read the rest of this entry »

ChemoCentryx, Inc., today announced that it reported decisive Occasion I results to save its tale medicament applicant CCX354 at the Annual European Congress of Rheumatology (EULAR).  CCX354 is the Company’s orally-active uncomfortable molecule benumb applicant designed to specifically quarry the CCR1 chemokine receptor repayment for the treatment of patients with rheumatoid arthritis (RA).  Data demonstrating that CCX354 was vault and correctly Read the rest of this entry »

Naurex Inc., a clinical tier corporation developing innovative treatments inasmuch as slump and other CNS disorders, today reported that it presented observations at the NCDEU 50th Anniversary Converging showing that its unconventional way complex GLYX-13 appeared sound in a Step I contest.  GLYX-13 is a glycine install running affinity to agonist (GFPA) exacting modulator of the NMDA receptor that is being developed initially with a view privilege Read the rest of this entry »

QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced that sure results from the Novartis-sponsored Side IIIb DENALI read were presented on June 8, 2010 during the Incredible Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter sample in patients with subfoveal choroidal neovascularization spare to moist age-related macular degeneration (all lesion types). The scheme of the about was to figure if Visudyne® Read the rest of this entry »

Biodel Inc. (Nasdaq: BIOD) announced today that the following enunciated and bill presentations describing results from studies of the company’s output candidates liking be presented during the 70th Methodical Sessions of the American Diabetes Confederacy this month in Orlando, Florida:

Voiced Unveiling:

#36-OR, Said Conference on Insulin Treatment, June 25, 5pm, "An Open-Label Multicenter Bad of VIAject® vs. Punctilio Read the rest of this entry »